Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Trinity Biotech (TRIB) Other Non-Current Liabilities (2022 - 2025)

Historic Other Non-Current Liabilities for Trinity Biotech (TRIB) over the last 4 years, with Q2 2025 value amounting to $1.8 million.

  • Trinity Biotech's Other Non-Current Liabilities rose 2749.31% to $1.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $1.8 million, marking a year-over-year increase of 2749.31%. This contributed to the annual value of $1.8 million for FY2024, which is 24467.68% up from last year.
  • Latest data reveals that Trinity Biotech reported Other Non-Current Liabilities of $1.8 million as of Q2 2025, which was up 2749.31% from $1.8 million recorded in Q4 2024.
  • Trinity Biotech's Other Non-Current Liabilities' 5-year high stood at $2.0 million during Q2 2022, with a 5-year trough of $526000.0 in Q4 2023.
  • Moreover, its 4-year median value for Other Non-Current Liabilities was $1.5 million (2023), whereas its average is $1.4 million.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first tumbled by 6647.55% in 2023, then skyrocketed by 24467.68% in 2024.
  • Quarter analysis of 4 years shows Trinity Biotech's Other Non-Current Liabilities stood at $1.6 million in 2022, then tumbled by 66.48% to $526000.0 in 2023, then skyrocketed by 244.68% to $1.8 million in 2024, then increased by 1.54% to $1.8 million in 2025.
  • Its last three reported values are $1.8 million in Q2 2025, $1.8 million for Q4 2024, and $596000.0 during Q3 2024.